内分泌疗法辅助或新辅助治疗乳腺癌：选择治疗的最佳药物、时机和持续时间

　　2016年4月22日，《中国临床肿瘤学》在线发表了复旦大学李俊杰、邵志敏教授的英语综述《内分泌疗法辅助或新辅助治疗乳腺癌：选择治疗的最佳药物、时机和持续时间》。

　　本微信为上海国际乳腺癌论坛（SIBCS）内部学术交流微信，仅供SIBCS参会人员、乳腺癌专业人士和乳腺癌专业英语爱好者参考，并非向患者或家属提供疾病诊治咨询服务的聊天论坛。除非特别声明，本微信登载的所有文章不代表本微信编委会和编辑部的观点。如因参考本微信登载的文章治疗后出现不良反应、损伤或死亡，本微信编委会和编辑部不承担任何法律责任。

　　乳腺癌诊治是非常复杂、非常严肃、非常有针对性的过程，每位患者病情不同，即使即使同一位患者在不同时期的病情也有所不同，需要具体病情具体分析，需要患者本人前往正规医院专科就诊。看病治病与读书教书一样，不可能在微信进行。希望患者或家属不要在微信盲目咨询，以免重复“魏则西”的悲剧。本微信恕不回复任何疾病诊治或药品相关问题，敬请谅解！

Chin Clin Oncol. 2016 Apr 22. [Epub ahead of print]

Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer: selecting the best agents, the timing and duration of treatment.

Li JJ, Shao ZM.

Department of Breast Surgery, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Hormone receptor (HR) positive breast cancers represent the vast majority of breast cancers. Adjuvant and/or neoadjuvant endocrine therapy is highly effective and appropriate for nearly all women with hormone receptor positive tumors. Adjuvant tamoxifen (TAM) is a major endocrine treatment option, which has been found to be effective in both premenopausal and postmenopausal patients. Considerable evidence has been accrued of a benefit for ovarian ablation or suppression (OA/S) in premenopausal patients, for aromatase inhibitors (AIS) in postmenopausal patients, for the longer duration of adjuvant endocrine therapy and for the clinical utility of neoadjuvant endocrine therapy. Clinical practice guidelines should keep changing with developing evidence-based practice guidelines pertaining to breast cancer care. The present publication conducted a comprehensive systematic review of the literature addressing the use of endocrine therapy as adjuvant or neoadjuvant therapy for hormone receptor positive breast cancer, focusing on selecting the best agents for both premenopausal and postmenopausal patients, as well as the optimal duration of such treatment.

KEYWORDS: Breast cancer; adjuvant; endocrine therapy; neoadjuvant

PMID: 27164856

PII: cco.2016.03.24

DOI: 10.21037/cco.2016.03.24